Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
Eric L. Simpson, Joseph F. Merola, Jonathan I. Silverberg, et al.
British Journal of Dermatology (2022) Vol. 187, Iss. 6, pp. 888-899
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
Pavel Kolkhir, Cezmi A. Akdiş, Mübeccel Akdiş, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 9, pp. 743-767
Closed Access | Times Cited: 67
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 48
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors
Richard W. Kim, Megan Lam, Katrina Abuabara, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 179-193
Closed Access | Times Cited: 19
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
Linda Stein Gold, Diamant Thaçi, Jacob P. Thyssen, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 4, pp. 595-607
Open Access | Times Cited: 32
The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update
Tubanur Çetinarslan, Lisa Kümper, Regina Fölster‐Holst
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 26
Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study
Axel De Greef, Pierre‐Dominique Ghislain, Audrey Bulinckx, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 4, pp. 299-306
Open Access | Times Cited: 23
Skin Barrier in Atopic Dermatitis
Matthias Schmuth, Sonja Eckmann, Verena Moosbrugger‐Martinz, et al.
Journal of Investigative Dermatology (2024) Vol. 144, Iss. 5, pp. 989-1000.e1
Closed Access | Times Cited: 12
Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks
Teppei Hagino, Risa Hamada, Mai Yoshida, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 12
Infections in Patients with Atopic Dermatitis and the Influence of Treatment
Maddalena Napolitano, Maria Esposito, Maria Concetta Fargnoli, et al.
American Journal of Clinical Dermatology (2025)
Open Access | Times Cited: 1
Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan
Teppei Hagino, Akihiko Uchiyama, Marina Onda, et al.
Dermatitis (2025)
Closed Access | Times Cited: 1
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
Amalie Thorsti Møller Rønnstad, Christopher G. Bunick, Raj Chovatiya, et al.
American Journal of Clinical Dermatology (2025)
Closed Access | Times Cited: 1
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis
Katarzyna Waligóra-Dziwak, Aleksandra Dańczak‐Pazdrowska, Dorota Jenerowicz
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4001-4001
Open Access | Times Cited: 8
Biologic and Small Molecule Therapy in Atopic Dermatitis
Mahek Shergill, Barinder Bajwa, Orhan Yilmaz, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1841-1841
Open Access | Times Cited: 6
Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis
Joseph F. Merola, Daniel Butler, Thomas Mark, et al.
JAMA Dermatology (2023) Vol. 159, Iss. 10, pp. 1119-1119
Open Access | Times Cited: 15
A Review of Existing and New Treatments for the Management of Hand Eczema
Jessica S. S. Ho, Sonja Molin
Journal of Cutaneous Medicine and Surgery (2023) Vol. 27, Iss. 5, pp. 493-503
Open Access | Times Cited: 14
Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics
Hwa Jung Yook, Ji Hyun Lee
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5164-5164
Open Access | Times Cited: 4
Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study)
Z. Reguiaï, Pierre André Becherel, Jean Perrot, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 11, pp. 2149-2155
Closed Access | Times Cited: 4
Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study
Ersilia Tolino, Luca Ambrosio, Nicoletta Bernardini, et al.
Dermatology and Therapy (2025)
Open Access
Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Annals of Dermatology (2025) Vol. 37
Open Access
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years
Raj Chovatiya, Simone Ribero, Andreas Wollenberg, et al.
American Journal of Clinical Dermatology (2025)
Open Access
Association of Tralokinumab and Adalimumab: Good Tolerance and Efficacy in a Case of Severe Atopic Dermatitis and Juvenile Idiopathic Arthritis
F. Rakotonandrasana, E. Puzenat, Astrid Ducournau, et al.
JEADV Clinical Practice (2025)
Open Access
At The Interface: Small-Molecule Inhibitors of Soluble Cytokines
Raavi, Angela N. Koehler, Arturo J. Vegas
Chemical Reviews (2025)
Closed Access
Clinical Recommendations for the Perioperative Management of Biologic Medications for Nonrheumatologic Diseases in Total Joint Arthroplasty
A. Rodriguez Moya, Pooya M. Tehrany, Kassem Ghayyad, et al.
JBJS Reviews (2025) Vol. 13, Iss. 4
Closed Access
Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition
Eric L. Simpson, Emma Guttman‐Yassky, Lawrence F. Eichenfield, et al.
Allergy (2023) Vol. 78, Iss. 11, pp. 2875-2891
Open Access | Times Cited: 10
Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review
Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, et al.
Clinical Cosmetic and Investigational Dermatology (2025) Vol. Volume 18, pp. 311-317
Open Access
Page 1 - Next Page

Scroll to top